What is the official website of Johnson & Johnson Innovative Medicine ?

The official website of Johnson & Johnson Innovative Medicine is https://innovativemedicine.jnj.com/.

What is Johnson & Johnson Innovative Medicine's cybersecurity risk score?

Johnson & Johnson Innovative Medicine has an AI-generated cybersecurity risk score of 807 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Johnson & Johnson Innovative Medicine experienced?

According to Rankiteo, Johnson & Johnson Innovative Medicine currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Johnson & Johnson Innovative Medicine been affected by any supply chain cyber incidents ?

According to Rankiteo, Johnson & Johnson Innovative Medicine has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Johnson & Johnson Innovative Medicine have SOC 2 Type 1 certification ?

According to Rankiteo, Johnson & Johnson Innovative Medicine is not certified under SOC 2 Type 1.

Does Johnson & Johnson Innovative Medicine have SOC 2 Type 2 certification ?

According to Rankiteo, Johnson & Johnson Innovative Medicine does not hold a SOC 2 Type 2 certification.

Does Johnson & Johnson Innovative Medicine comply with GDPR ?

According to Rankiteo, Johnson & Johnson Innovative Medicine is not listed as GDPR compliant.

Does Johnson & Johnson Innovative Medicine have PCI DSS certification ?

According to Rankiteo, Johnson & Johnson Innovative Medicine does not currently maintain PCI DSS compliance.

Does Johnson & Johnson Innovative Medicine comply with HIPAA ?

According to Rankiteo, Johnson & Johnson Innovative Medicine is not compliant with HIPAA regulations.

Does Johnson & Johnson Innovative Medicine have ISO 27001 certification ?

According to Rankiteo,Johnson & Johnson Innovative Medicine is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Johnson & Johnson Innovative Medicine operate in ?

Johnson & Johnson Innovative Medicine operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Johnson & Johnson Innovative Medicine have ?

Johnson & Johnson Innovative Medicine employs approximately 37,729 people worldwide.

Does Johnson & Johnson Innovative Medicine own any subsidiaries ?

Johnson & Johnson Innovative Medicine presently has no subsidiaries across any sectors.

How many LinkedIn followers does Johnson & Johnson Innovative Medicine have ?

Johnson & Johnson Innovative Medicine's official LinkedIn profile has approximately 1,383,959 followers.

What is the NAICS classification code for Johnson & Johnson Innovative Medicine ?

Johnson & Johnson Innovative Medicine is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Johnson & Johnson Innovative Medicine have a Crunchbase profile ?

Yes, Johnson & Johnson Innovative Medicine has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/janssen.

Does Johnson & Johnson Innovative Medicine have a LinkedIn profile ?

Yes, Johnson & Johnson Innovative Medicine maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/jnjinnovativemedicine.

How many cybersecurity incidents has Johnson & Johnson Innovative Medicine experienced ?

As of July 14, 2026, Rankiteo reports that Johnson & Johnson Innovative Medicine has not experienced any cybersecurity incidents.

How many peer or competitor companies does Johnson & Johnson Innovative Medicine have ?

Johnson & Johnson Innovative Medicine has an estimated 5,708 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

JJIM

Boost Score +25 with badge (5 left)

807

/1000

Good

832

/1000

Good

Johnson & Johnson Innovative Medicine Vendor Cyber Rating & Cyber Score

jnj.com

cb in

Add Your Compliance Badge

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

JJIM A.I CyberSecurity Scoring

Scoring History

JJIM

Johnson & Johnson Innovative Medicine CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

JJIM Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for JJIM

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.

Incident Types JJIM vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.

Incident History - JJIM (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Johnson & Johnson Innovative Medicine Subsidiaries

JJIM

Pharmaceutical Manufacturing

Website: https://innovativemedicine.jnj.com/

Company Size: 10,001+ employees

J&J Innovative Medicine BelgiumPharmaceutical Manufacturing

J&J Innovative Medicine NederlandGeneesmiddelenproductie

J&J Medical Affairs OncologyPharmaceutical Manufacturing

Johnson & Johnson Innovative Medicine, CanadaPharmaceutical Manufacturing

SPRAVATO® (esketamine) for HCPsPharmaceutical Manufacturing

Loading…

Johnson & Johnson Innovative Medicine Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Loading…

NEWS

Johnson & Johnson Innovative Medicine CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 12, 2026 11:02 PM

Veteran safety C.J. Gardner-Johnson signs with Bills

Free agent safety C. J. Gardner-Johnson is signing a one-year deal worth up to $6 million with the Buffalo Bills, agents Kevin Conner and...

Read Article

March 12, 2026 11:00 PM

Bears News: Chicago Loses DB to Buffalo Bills

According to ESPN's Adam Schefter, Chicago Bears free-agent safety CJ Gardner-Johnson has signed a one-year deal with the Buffalo Bills.

Read Article

March 12, 2026 10:56 PM

Trump's SAVE Act push creates new FISA problem for Mike Johnson

Reauthorizing Section 702 of FISA is shaping up to be a major headache for House Speaker Mike Johnson.

Read Article

March 12, 2026 10:55 PM

Johnson's 25 help Akron defeat Buffalo 73-70 in Mid-American Conference Tournament

Led by Tavari Johnson's 25 points, the Akron Zips defeated the Buffalo Bulls 73-70 in the Mid-American Conference Tournament on Thursday.

Read Article

March 12, 2026 10:54 PM

Former Bears defensive back CJ Gardner-Johnson signs with Bills

Gardner-Johnson appeared in 10 regular season games for Chicago, with two interceptions and 35 tackles...

Read Article

March 12, 2026 10:53 PM

Ex-Eagles DB, Super Bowl champion signing elsewhere in free agency

The Philadelphia Eagles won't be bringing back safety C.J. Gardner-Johnson, who is signing with the Buffalo Bills.

Read Article

March 12, 2026 10:52 PM

Bills sign former Eagles safety C.J. Gardner-Johnson to one-year deal

Former Eagles free-agent safety C.J. Gardner-Johnson signed a one-year deal worth up to $6 million with the Bills after finishing the 2025...

Read Article

March 12, 2026 10:50 PM

Wisconsin senators react to Iran conflict: Baldwin seeks hearings, Johnson backs President Trump

As the conflict with Iran continues, Wisconsin U.S. Senators Ron Johnson and Tammy Baldwin are speaking out.

Read Article

March 12, 2026 10:50 PM

Wisconsin senators react to Iran conflict: Baldwin seeks hearings, Johnson supports Trump

As the conflict with Iran continues, Wisconsin U.S. Senators Ron Johnson and Tammy Baldwin are speaking out.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-58489

SUMMARY

HedgeDoc is an open source, real-time collaborative markdown notes application. Prior to 1.11.0, the GitHub Gist export flow created an OAuth2 state value but only checked that it was present rather than validating it against the value expected for the user's session. Because the state was not properly validated, an attacker could forge a callback URL containing their own valid GitHub OAuth code. When processing the callback, HedgeDoc used the victim's logged-in session to select which note to export, but the attacker's authorization code to determine which GitHub account received it. As a result, a logged-in victim who clicked a crafted link could export their own private, protected, or limited note directly into a Gist controlled by the attacker. This issue has been fixed in version 1.11.0.

Published

Date2026-07-13

Updated

Date2026-07-13

RISK INFORMATION (Score: )

cvss4

Base Score: 6.8

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:L/UI:A/VC:H/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-58486

SUMMARY

HedgeDoc is an open source, real-time, collaborative, markdown notes application. Prior to version 1.11.0, HedgeDoc was vulnerable to a YAML alias bomb due to unsafe processing of the note frontmatter. HedgeDoc parsed frontmatter with js-yaml.load (js-yaml v3) via @hedgedoc/meta-marked, which resolved YAML anchor aliases. A compact malicious payload could therefore expand into a huge object structure, consuming excessive CPU. This expansion ran on every request to the publish view (/s/<shortid>) and, when placed under the opengraph key, the editor view (/<noteId>). A ten-level alias bomb could block the single Node.js event loop for roughly 235 seconds per request, causing concurrent requests to hang or drop and rendering the instance unavailable (DoS). Because the note was stored in the database, the impact survived process restarts until the note was removed. toobusy-js did not reliably mitigate the worst cases, as the event loop was saturated before the middleware could respond. This issue was fixed in version 1.11.0.

Published

Date2026-07-13

Updated

Date2026-07-13

RISK INFORMATION (Score: )

cvss4

Base Score: 8.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-58102

SUMMARY

Crypt::OpenSSL::X509 versions before 2.1.3 for Perl allow a heap out-of-bounds read via a long certificate extension OID in hv_exts. When building the extension hash (via extensions(), extensions_by_long_name(), extensions_by_oid(), or has_extension_oid()), the code passes OBJ_obj2txt()'s return value as the hash-key length; because that value is the OID's full text length rather than the bytes written to the fixed-size buffer (129 bytes), an OID whose text is longer than the 129-byte buffer causes a read past the allocation, exposing adjacent heap memory as the returned hash key. extensions_by_name() uses the static shortname path and is not affected.

Published

Date2026-07-13

Updated

Date2026-07-13

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-58101

SUMMARY

Crypt::OpenSSL::X509 versions before 2.1.3 for Perl allow denial of service via NULL pointer dereference. X509V3_EXT_d2i(ext) returns NULL when an extension's DER value fails to parse. basicC, ia5string, and auth_att dereference its result without a NULL check. keyid_data also dereferences akid->keyid, which is NULL for an empty AKI SEQUENCE (DER 30 00) even when the parse succeeds. A caller invoking an affected helper on an extension from an untrusted certificate triggers a SIGSEGV that crashes the Perl process.

Published

Date2026-07-13

Updated

Date2026-07-13

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-57856

SUMMARY

Cockpit CMS contains a path traversal vulnerability in the Bucket file storage API (/system/buckets/api). The api() method in modules/System/Controller/Buckets.php sanitizes the bucket name with preg_replace('/[^a-zA-Z0-9-_\\.]/','', $bucket), which permits '..' and '../' sequences. The sanitized value is interpolated into a Flysystem path as uploads://buckets/{bucket}. Flysystem's WhitespacePathNormalizer resolves 'buckets/..' to the empty string (the uploads storage root) without raising PathTraversalDetected because the '..' has a preceding component to consume. An authenticated low-privileged user can send a crafted request with a '../' bucket name to list, upload, and delete files across all buckets, including those belonging to other users or roles

Published

Date2026-07-13

Updated

Date2026-07-13

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…